Real-world effectiveness and safety of voclosporin in the treatment of lupus nephritis with poor prognostic clinical and histological factors (ERA 2025) - Apr 15, 2025 - Abstract #2018; Pres time: Jun 5, 2025; 12:39 PM - 12:42 PM; Location: Mozart Die Zauberflöte; "For the treatment of the current LN episode, before starting VCS, one patient had been treated with a combination of mycophenolate mofetil (MMF) and tacrolimus; another had received cyclophosphamide, MMF, tacrolimus, belimumab, and rituximab; a third had received MMF, tacrolimus, and rituximab; while the remaining two patients started VCS immediately after cyclophosphamide (ELNT schedule) as first-line therapy due to poor prognostic histological criteria. At the time of VCS initiation, all patients were on hydroxychloroquine, and three were receiving prednisone (median: 5 mg/day); three patients were switched from MMF and tacrolimus to MMF and VCS, while the remaining two started VCS immediately after cyclophosphamide as first-line therapy... VCS was effective, in the short term, for optimizing treatment in LN patients with incomplete renal remission despite treatment or with poor prognostic histological factors, in real-world settings and with a good safety and..."
Clinical • Real-world • Real-world effectiveness • Real-world evidence • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Marc Xipell1; Cecilia Garbarino1; Raul Jordà1; Elena Guillén Olmos1; Maria Iraola1; Maria Argudo1; Miquel Blasco Pelicano1; Jose A. Gómez-Puerta1; Ricard Cervera1; Gerard Espinosa1; Luis Fernando Quintana Porras1
|